Abeona Therapeutics (ABEO) Stifel Virtual Cell Therapy Forum summary

Company overview and strategic direction

• Transitioning from R&D to commercial stage with a clear path to profitability in cell and gene therapy for serious diseases.

• Lead program, pz-cel, targets recessive dystrophic epidermolysis bullosa (RDEB) with autologous engineered cell therapy.

• Additional pipeline includes preclinical AAV-based gene therapies for ophthalmology and partnered programs with Taysha Gene Therapies and Ultragenyx.

Clinical program and differentiation

• Pz-cel demonstrated sustained wound healing and pain reduction in chronic, large wounds after a single application.

• Phase 1/2a and pivotal Phase 3 VIITAL studies showed statistically significant healing in the most challenging wounds, with durability confirmed up to 6-8 years.

• Treated wounds averaged six years of chronicity and showed 0% healing in control arms, highlighting the therapy's impact.

• Efficacy observed across multiple anatomical locations, with potential benefit beyond the toughest wounds.

• No squamous cell carcinomas observed in treated sites, though not yet statistically robust for prevention claims.

Safety and regulatory status

• Gamma-retroviral vector used for gene integration; no replication-competent retrovirus detected in over 120 samples.

• Insertional oncogenesis risk considered extremely low, with strict controls and supportive literature.

• Risk-benefit profile seen as highly favorable given the disease's high cancer risk.

• Current regulatory focus is on CMC (chemistry, manufacturing, controls) issues, not efficacy or safety.